The race for the tiniest waist just got even more competitive.
New clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18% of their body weight in under a year.
The findings suggest the newcomer could one day outperform some of the biggest names in the booming GLP-1 market , including Wegovy and Mounjaro.
In the 48-week trial, researchers from Fudan University in Shanghai recruited 567 adults who were overweight or obese and divided them into four groups.
Three groups received weekly injections of ribupatide at doses of 2 milligrams, 4 milligrams or 6 milligrams, while the fourth received a placebo.
Behind…
Read the full article at NYPOST.COM



